Inclusion Criteria:
* Subjects volunteered to join the study, signed informed consent, had good compliance, and cooperated with follow-up.
* Aged 18-60 years, male or female.
* Subjects pathologically diagnosed non-Hodgkin's lymphoma, and intend to undergo autologous hematopoietic stem cell transplantation.
* ECOG score 0-1.
* Meet the following requirements: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times the upper limit of normal value (ULN), total bilirubin (TBIL) ≤1.5×ULN (AST and ALT≤5×ULN are allowed if liver invasion occurs); serum creatinine ≤1.5×ULN; international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5×ULN; ECG examination was normal or abnormal without clinical significance, cardiac ultrasound showed left ventricular ejection fraction (LVEF) greater than 60, or CK-MB is normal, pro-BNP less than 900 pg/mL.
* Female subjects have negative serum pregnancy test result. Subjects use highly effective birth control methods throughout the trial.
Exclusion Criteria:
* Previous recipients of mitoxantrone or mitoxantrone liposome; previous treatment with doxorubicin or other anthracyclines, with a cumulative dose of doxorubicin \> 360 mg/m2 (for other anthracyclines, 1 mg doxorubicin is equivalent to 2 mg epirubicin).
* Hypersensitivity to any study drug or its component.
* Uncontrolled systemic diseases (e.g., active infections, uncontrolled hypertension, diabetes, etc.) .
* Cardiac function and disease meet one of the following conditions: a) Long QTc syndrome or QTc interval \>480 ms; b) Complete left bundle branch block, degree II or III atrioventricular block; c) Severe uncontrolled arrhythmias that require medical treatment; d) New York College of Cardiology Grade ≥ III; e) Cardiac ejection fraction (LVEF) less than 60%; f) A history of myocardial infarction, unstable angina pectoris, severely unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities within 6 months prior to recruitment.
* Active hepatitis B and C infection (positive HBV sAg and HBV-DNA more than 1x10\^3 copies/mL; HCV-RNA more than 1x10\^3 copies/mL) .
* Positive HIV antibody.
* Previous or current co-occurrence of other malignancies (except for effectively controlled non-melanoma basal cell carcinoma of the skin, breast/cervical carcinoma in situ, and other malignancies that have been effectively controlled without treatment in the past 5 years) .
* Primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at the time of recruitment.
* Pregnant or lactating female subjects and those who do not want to take contraceptive measures.
* Drug abuse (non-medical use of narcotic drugs or psychotropic drugs) or drug dependence (sedative hypnotics, analgesics, anesthetics, excitants and psychotropic drugs, etc.).
* A history of mental disease or cognitive impairment.
* Other conditions that the investigator determined are not suitable for participation in the study.
